In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chiron/PowderJect: US Snaps Up Europe's Best

Executive Summary

Chiron's acquisition of PowderJect is the most recent sign that the vaccines industry is coming of age, taking the field's only two mid-sized players up among the top-ranking Big Pharma. This deal was largely about infrastructure. But it suggests any European biotech with a valuable asset--be it product or distribution network--is an attractive takeover target for US firms.
Advertisement

Related Content

PowderMed's Vaccines: Out of Chiron, Into the Clinic
Bioteching UCB-and Maybe Mid-Sized Pharma, Too
PowderMed's Vaccines: Out of Chiron, Into the Clinic
More Funding Options for European biotech
Biotech Money, Where Art Thou?
European Biotech M&A: Often Last Resort, but Welcome Nevertheless
Shire Lays a Stake in Vaccines
Fluvirin: PowderJect's Best Shot
Versicor/Biosearch Italia: Merging as Equals
Long End of the Stick

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel